Imugene signs research agreement with University of Vienna

THE ROADHOUSE PHARMACY: Imugene Limited (ASX: IMU) has signed an agreement to conduct preclinical immunology experiments in preparation for the 2015 clinical trials of HER-Vaxx.

The agreement has been signed with Professor Ursula Wiedermann and her research group at the Medical University of Vienna.

Imugene said the research will focus on peptides and peptide-incorporated influenza virosomes to be used in the upcoming HER-Vaxx Phase II clinical trial.

Professor Wiedermann is head of the Institute of Specific Prophylaxis and Tropical Medicine at the Medical University of Vienna and her research group within the department will carry out the work.

Professor Wiedermann is a member of the Imugene Scientific Advisory Board and was the principal investigator for the preclinical development of HER-axx.

She has led the design of the HER-Vaxx Phase II study for gastric cancer due to commence in 2015.

“We expect this high quality research and the results subsequently generated by Professor Wiedermann and her team, to support our Phase II trial design and IND application to the US FDA,” Imugene CEO Charles Walker said in the company’s announcement to the Australian Securities Exchange.

Professor Wiedermann is a Professor in Vaccinology who has been published in over 100 peer-reviewed publications and is a renowned presenter at medical innovation conferences worldwide.

As well as the preclinical development of HER-Vaxx, she performed the Phase I clinical trial in metastatic breast cancer patients with Professor Christoph Zielinski.

Website: www.imugene.com